Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Key Points
HER2 expression varies significantly between prostate cancer and urothelial carcinoma, impacting therapy decisions.
Analysis indicates clear correlations between ERBB2 genomic status and HER2 IHC across both cancer types.
Box plots demonstrate relationships between HER2 RNA expression and cancer types, highlighting diagnostic potentials.
Understanding HER2 can guide targeted therapies for prostate and urothelial cancers, supporting personalized treatments.
Abstract
A and B, Mosaic plots indicating the relationship between ERBB2 genomic status as assessed by unadjusted copy number and HER2 IHC in (A) prostate and (B) urothelial cancers. C and D, Box plots indicating the relationship between HER2 RNA expression with (C) prostate and (D) urothelial cancers. PC, prostate cancer; UC, urothelial carcinoma.